Developing a cost effectiveness story to support pricing and market access negotiations

Developing a cost effectiveness story to support pricing and market access negotiations

Life Sciences Strategy

A pharma company retained CRA's Life Sciences Practice to build a value story to show ability of a drug to reduce disease progression in rare disease patients intolerant to standard therapy. 

CRA approach

  • Create transparency on most current scientific data and references linked to the value story components
  • Build supportive arguments with clinical evidence to show that a drug is able to slow down disease progression in a special population of patients intolerant to standard therapy
  • Underline additional supporting evidence and data analyses required to further strengthen the brands claim

Client impact

  • Create transparency on most current scientific data and references linked to the value story components 
  • Build supportive arguments with clinical evidence to show that a drug is able to slow down disease progression in a special population of patients intolerant to standard therapy
  • Underline additional supporting evidence and data analyses required to further strengthen the brands claim